|
|
Article: Genmab Announces Positive Phase I/II Results for HuMax-CD4 to Treat Rheumatoid Arthritis; Data Presented at the American College of Rheumatology Meeting.
- Article from:
- PR Newswire
- Article date:
- November 1, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHILADELPHIA, Nov. 1 /PRNewswire/ --
Genmab A/S (CSE: GEN; Neuer: GE9) announced today positive results from a Phase I/II clinical trial of HuMax- CD4, a fully human antibody used to treat patients with rheumatoid arthritis. HuMax-CD4 was well tolerated in this dose escalating, placebo controlled study of 35 patients with severe rheumatoid arthritis, and there was no evidence of depletion of patients' CD4 positive T cells. Furthermore, in this single dose study, in the four highest dose cohorts, 0.5, 1, 2 and 4 mg/kg, fifty percent of the treated patients achieved favorable responses to the antibody, as measured by objective criteria that have been defined by ...